Profile
Dr. Roger Léger is Founder at Ulysses Pharmaceuticals Pvt Ltd.
and Vice President-Research Consulting at Indel Therapeutics, Inc.
Dr. Léger was previously employed as a Director-Medicinal Chemistry by ConjuChem Biotechnologies, Inc., a Principal by Essential Therapeutics, Inc., and Vice President-Research by Ulysses Pharmaceuticals Products, Inc.
Roger Léger active positions
| Companies | Position | Start |
|---|---|---|
Indel Therapeutics, Inc.
 Indel Therapeutics, Inc. BiotechnologyHealth Technology Indel Therapeutics, Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, and commercialization of antibiotics to address the health crisis caused by antibiotics resistance. The firm’s programs are based on Indel's paradigm-changing antimicrobial drug discovery platform that has opened drug targets for the treatment of bacterial and parasitic infections, and potentially, fungal and viral infections. The company was founded by Malcolm C. Kendall in 2008 and is headquartered in Vancouver, Canada.^ ^ | Corporate Officer/Principal | 29/10/2012 |
Former positions of Roger Léger
| Companies | Position | End |
|---|---|---|
Ulysses Pharmaceuticals Pvt Ltd.
 Ulysses Pharmaceuticals Pvt Ltd. Pharmaceuticals: OtherHealth Technology Ulysses Pharmaceuticals Pvt Ltd. provides homeopathic modern medicines. It engages in the discovery and development of novel and safe antimicrobial agents for the treatment of severe and recurrent infections occurring in human. The company was founded in July 2001 and is headquartered in Kolkata, India. | Founder | - |
ConjuChem Biotechnologies, Inc.
 ConjuChem Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology ConjuChem Biotechnologies, Inc. develops peptide based pharmaceuticals. Its peptide products are used to treat diseases such as congestive heart failure, diabetes, HIV/AIDS and human growth deficiencies. ConjuChem Biotechnologies is a research and development company that develops technology that binds peptides to albumin in order to extend the half life of drugs from minutes to days. The company was founded on August 25, 2009 and is headquartered in Montréal, Canada. | Corporate Officer/Principal | - |
Essential Therapeutics, Inc.
 Essential Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Essential Therapeutics, Inc. manufactures pharmaceutical goods for viral and fungal infections | Corporate Officer/Principal | - |
Ulysses Pharmaceuticals Products, Inc.
 Ulysses Pharmaceuticals Products, Inc. Pharmaceuticals: MajorHealth Technology Ulysses Pharmaceuticals discovers and develops antibiotics for empiric monotherapy to control resistant bacterial infections. The company was founded in December 2001 by Suzanne Chamberland, Roger Léger, and François Malouin and is headquartered in Sherbrooke, Canada | Chief Tech/Sci/R&D Officer | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Indel Therapeutics, Inc.
Indel Therapeutics, Inc. BiotechnologyHealth Technology Indel Therapeutics, Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, and commercialization of antibiotics to address the health crisis caused by antibiotics resistance. The firm’s programs are based on Indel's paradigm-changing antimicrobial drug discovery platform that has opened drug targets for the treatment of bacterial and parasitic infections, and potentially, fungal and viral infections. The company was founded by Malcolm C. Kendall in 2008 and is headquartered in Vancouver, Canada.^ ^ | Health Technology |
Ulysses Pharmaceuticals Products, Inc.
Ulysses Pharmaceuticals Products, Inc. Pharmaceuticals: MajorHealth Technology Ulysses Pharmaceuticals discovers and develops antibiotics for empiric monotherapy to control resistant bacterial infections. The company was founded in December 2001 by Suzanne Chamberland, Roger Léger, and François Malouin and is headquartered in Sherbrooke, Canada | Health Technology |
ConjuChem Biotechnologies, Inc.
ConjuChem Biotechnologies, Inc. Pharmaceuticals: MajorHealth Technology ConjuChem Biotechnologies, Inc. develops peptide based pharmaceuticals. Its peptide products are used to treat diseases such as congestive heart failure, diabetes, HIV/AIDS and human growth deficiencies. ConjuChem Biotechnologies is a research and development company that develops technology that binds peptides to albumin in order to extend the half life of drugs from minutes to days. The company was founded on August 25, 2009 and is headquartered in Montréal, Canada. | Health Technology |
Essential Therapeutics, Inc.
Essential Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Essential Therapeutics, Inc. manufactures pharmaceutical goods for viral and fungal infections | Health Technology |
Ulysses Pharmaceuticals Pvt Ltd.
Ulysses Pharmaceuticals Pvt Ltd. Pharmaceuticals: OtherHealth Technology Ulysses Pharmaceuticals Pvt Ltd. provides homeopathic modern medicines. It engages in the discovery and development of novel and safe antimicrobial agents for the treatment of severe and recurrent infections occurring in human. The company was founded in July 2001 and is headquartered in Kolkata, India. | Health Technology |
- Stock Market
- Insiders
- Roger Léger
